Agios Pharmaceuticals, Inc. (AGIO)
Fuera de horario:
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 383
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Brian M. Goff M.B.A. | CEO & Director | 1.46M | N/D | 1969 |
| Ms. Cecilia Jones | Chief Financial Officer | 751.48k | N/D | 1975 |
| Mr. James William Burns | Corporate Secretary & Chief Legal Officer | 1.02M | N/D | 1978 |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 1.25M | N/D | 1980 |
| Ms. Tsveta Milanova | Chief Commercial Officer | 939.05k | N/D | 1977 |
| Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | 50k | N/D | 1949 |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | 1946 |
| Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | N/D | N/D | 1953 |
| Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | 1956 |
| Mr. T. J. Washburn | Principal Accounting Officer | N/D | N/D | 1982 |
Descripción
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Agios Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 5. Las puntuaciones principales son Auditoría: 6; Junta: 3; Derechos del accionista: 7; Compensación: 6.
